Clinical trials: T2DM
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
- Trial name
- MARITIME-2 (NCT06858878)
- Testing
- Maridebart cafraglutide
- Where
- 187 sites in United States, Argentina and 11 more
- Volunteers
- 1,105 people
- Sponsor
- Amgen
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Type 2 Diabetes Mellitus, Elderly
Phase 4 Study in the Elderly Patients With T2DM
The study will assess the incidence of Hypoglycemia: Percent of patients presenting no hypoglycemia (confirmed events with SMBG and severe episodes) over 6 months follow up in T2DM patients treated with a DPP-4 inhibitor or…
- Trial name
- GLYCEMIA (NCT01238978)
- Testing
- Vildagliptin, "Usual Care"
- Where
- 15 sites in France
- Volunteers
- 46 people
- Sponsor
- Novartis
Type 2 Diabetes
The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus
SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in diabetes subjects.
- Trial name
- NCT05426018
- Testing
- SY-009 capsules
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Type 2 Diabetes
A Study of HS-20094 in Patients With T2DM
This is a 32-week, phase 2, randomized study, HS-20094 and placebo were double-blind, dulaglutide was open-label. Adults with T2D inadequately controlled with diet and exercise alone or with stable metformin, an HbA1c (glycated…
- Trial name
- NCT06901648
- Testing
- HS-20094, Dulaglutide, Palcebo
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07691203
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes (T2DM)
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.
- Trial name
- NCT07046273
- Testing
- F027, Ozempic®
- Volunteers
- 496 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Diabetes Mellitus, Type 2
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM.
- Trial name
- IMPERIUM (NCT02072096)
- Testing
- Glimepiride, Metformin, Pioglitazone
- Where
- 34 sites in United States, Austria and 3 more
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company